On the Record · Grifols
Grifols competitors, on the record
The companies Grifols itself names as competitors in its annual reports, 2023 to 2025, each with the sentence it appears in and the filing it came from.
Who Grifols names
| Company | Named in |
|---|---|
| AATec Medical | 2025 |
| Argenx | 2025 |
| CSL | 2025 |
| GC Biopharma | 2025 |
| Genetech | 2025 |
| Mereo Biopharma | 2025 |
| Takeda | 2025 |
In its own words
AATec Medical, Mereo Biopharma
Word for word“In the therapeutic area of pulmonology, specifically alpha-1-antitrypsin augmentation therapy (“AAT”), we face competition from other companies such as Mereo Biopharma and AATec Medical in researching and developing novel oral and inhaled recombinant AAT therapies, respectively.” 20-F for 2025
Argenx, GC Biopharma
Word for word“GC Biopharma introduced its 10% IVIG product, Alyglo TM , to the U.S. market in 2024 and Argenx obtained FDA approval in 2021 for VYVGART (IV) and in 2024 for VYVGART Hytrulo (subcutaneous), a non-plasma derived product that would treat patients with chronic inflammatory demyelinating polyneuropathy (“CIDP”).” 20-F for 2025
CSL, Takeda
Word for word“In the area of alpha1-proteinase inhibitor deficiency, CSL’s Respreeza/Zemaira and Takeda’s Aralast (lyo)/Glassia (liquid) are competing with our Prolastin product.” 20-F for 2025
Genetech
Word for word“Genetech’s Hemlibra, a non-plasma product to control bleeding in patients with hemophilia A, is another competitor in the hemophilia market.” 20-F for 2025
Read from Grifols’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-04-17. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.